Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study
Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity. A prospective single-centre test-negative d...
Gespeichert in:
| Veröffentlicht in: | The Lancet regional health. Europe 2023-02, Vol.25, p.100552-100552, Article 100552 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100552 |
|---|---|
| container_issue | |
| container_start_page | 100552 |
| container_title | The Lancet regional health. Europe |
| container_volume | 25 |
| creator | Chatzilena, Anastasia Hyams, Catherine Challen, Rob Marlow, Robin King, Jade Adegbite, David Kinney, Jane Clout, Madeleine Maskell, Nick Oliver, Jennifer Danon, Leon Finn, Adam Morley, Anna Langdon, Amelia Turner, Anabella Mattocks, Anya Osborne, Bethany Grimes, Charli Mitchell, Claire Bridgeman, Emma Scott, Emma Perkins, Fiona Bayley, Francesca Ruffino, Gabriella Valentine, Gabriella Tilzey, Grace Kellett Wright, Johanna Brzezinska, Julia Cloake, Julie Milutinovic, Katarina Helliker, Kate Maughan, Katie Fox, Kazminder Minou, Konstantina Ward, Lana Fleming, Leah Morrison, Leigh Smart, Lily Wright, Louise Grimwood, Lucy Bellavia, Maddalena Vasquez, Marianne Garcia Gonzalez, Maria Jeenes-Flanagan, Milo Chang, Natalie Grace, Niall Manning, Nicola Griffiths, Oliver Croxford, Pip Sequenza, Peter Lazarus, Rajeka Walters, Rhian Marlow, Robin Heath, Robyn Antico, Rupert Nammuni Arachchge, Sandi Suppiah, Seevakumar Mona, Taslima Riaz, Tawassal Mackay, Vicki Maseko, Zandile Taylor, Zoe Friedrich, Zsolt Szasz-Benczur, Zsuzsa |
| description | Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.
A prospective single-centre test-negative design case–control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO2 (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and community infection prevalence.
935 controls and 546 cases were hospitalised during the Delta period, with 721 controls and 372 cases hospitalised during the Omicron study period. Two-dose BNT162b2 was associated with VE 82.5% [95% confidence interval 76.2%–87.2%] against hospitalisation following Delta infection, 63.3% [26.9–81.8%], 58.5% [24.8–77.3%], and 51.5% [16.7–72.1%] against LOS >3 days, WHO COVID Score >5, and requirement for FiO2 >28% respectively. Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9–49.3%], with sensitivity analyses ranging from 28.8–72.6%. Protection against LOS >3 days, WHO COVID Score >5 and requirement for FiO2 >28% was 56.1% [20.6–76.5%], 58.8% [31.2–75.8%], and 41.5% [−0.4–66.3%], respectively. In the UK, BNT162b2 was prioritised for high-risk individuals and those aged >75 years. In the latter group we found a higher estimate of VE against hospitalisation of 47.2% [16.8–66.6%].
BNT162b2 vaccination results in risk reductions for hospitalisation and multiple patient outcomes following Delta and Omicron COVID-19 infection, particularly in older adults. BNT162b2 remains effective against severe SARS-CoV-2 disease.
AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer. |
| doi_str_mv | 10.1016/j.lanepe.2022.100552 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9728025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666776222002484</els_id><sourcerecordid>2753669139</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-21651b4425dbd1f186137a6d7626268938e64bccd6c1b2ffbae153a65451d4f03</originalsourceid><addsrcrecordid>eNp9UsFO3DAUDFWrgih_UFU-wiFpnpM4mx4qwUJbECpSoVwtx35hvcrai-0s2lv_oX_YL6k3Sym9VDk4z555njeeJHkLeQY5sPfzrBcGl5jRnNK4lVcVfZHsUcZYWteMvnz2v5sceD_P85xWUFAoXye7BatyVjewt7Nz1nUog16hQe-J7cjJ1xtgtKVkenV7fppCQ1ZCSm1E0NYQbcjSYUSPVYTPrF_qIHrtR4AnwijiI8IhUdqj8LghCTX0wZMHHWbk-vjbdTq1tyklp9gHQQ5PMsgY1Bk9GulXCy1dbD_uQ1bR5iiKcFqYQFoMD4iGXAwGSZweRsbF0K83Ff1ARBQYNW2HIgF9IAbvxFjJqObXj5_SmuBsT3wY1PpN8qoTvceDx3U_-f7p7Gb6Jb28-nw-Pb5MZcmKkFJgFbRlSSvVKuhgwqCoBVPR4PhNmmKCrGylVExCS7uuFQhVIVhVVqDKLi_2k4_bvsuhXaCS0UIner50eiHcmluh-b8nRs_4nV3xpqaT-HaxweFjA2fvhzgXX2gvsd8kwQ6e07oqGGugaCK03EKjjd477J6ugZxvAsTnfBsgvjGNbwMUae-eS3wi_YnL3xkwGrXS6LiXGo1EpV00nCur_3_Db5ZP13Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2753669139</pqid></control><display><type>article</type><title>Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chatzilena, Anastasia ; Hyams, Catherine ; Challen, Rob ; Marlow, Robin ; King, Jade ; Adegbite, David ; Kinney, Jane ; Clout, Madeleine ; Maskell, Nick ; Oliver, Jennifer ; Danon, Leon ; Finn, Adam ; Morley, Anna ; Langdon, Amelia ; Turner, Anabella ; Mattocks, Anya ; Osborne, Bethany ; Grimes, Charli ; Mitchell, Claire ; Bridgeman, Emma ; Scott, Emma ; Perkins, Fiona ; Bayley, Francesca ; Ruffino, Gabriella ; Valentine, Gabriella ; Tilzey, Grace ; Kellett Wright, Johanna ; Brzezinska, Julia ; Cloake, Julie ; Milutinovic, Katarina ; Helliker, Kate ; Maughan, Katie ; Fox, Kazminder ; Minou, Konstantina ; Ward, Lana ; Fleming, Leah ; Morrison, Leigh ; Smart, Lily ; Wright, Louise ; Grimwood, Lucy ; Bellavia, Maddalena ; Vasquez, Marianne ; Garcia Gonzalez, Maria ; Jeenes-Flanagan, Milo ; Chang, Natalie ; Grace, Niall ; Manning, Nicola ; Griffiths, Oliver ; Croxford, Pip ; Sequenza, Peter ; Lazarus, Rajeka ; Walters, Rhian ; Marlow, Robin ; Heath, Robyn ; Antico, Rupert ; Nammuni Arachchge, Sandi ; Suppiah, Seevakumar ; Mona, Taslima ; Riaz, Tawassal ; Mackay, Vicki ; Maseko, Zandile ; Taylor, Zoe ; Friedrich, Zsolt ; Szasz-Benczur, Zsuzsa</creator><creatorcontrib>Chatzilena, Anastasia ; Hyams, Catherine ; Challen, Rob ; Marlow, Robin ; King, Jade ; Adegbite, David ; Kinney, Jane ; Clout, Madeleine ; Maskell, Nick ; Oliver, Jennifer ; Danon, Leon ; Finn, Adam ; Morley, Anna ; Langdon, Amelia ; Turner, Anabella ; Mattocks, Anya ; Osborne, Bethany ; Grimes, Charli ; Mitchell, Claire ; Bridgeman, Emma ; Scott, Emma ; Perkins, Fiona ; Bayley, Francesca ; Ruffino, Gabriella ; Valentine, Gabriella ; Tilzey, Grace ; Kellett Wright, Johanna ; Brzezinska, Julia ; Cloake, Julie ; Milutinovic, Katarina ; Helliker, Kate ; Maughan, Katie ; Fox, Kazminder ; Minou, Konstantina ; Ward, Lana ; Fleming, Leah ; Morrison, Leigh ; Smart, Lily ; Wright, Louise ; Grimwood, Lucy ; Bellavia, Maddalena ; Vasquez, Marianne ; Garcia Gonzalez, Maria ; Jeenes-Flanagan, Milo ; Chang, Natalie ; Grace, Niall ; Manning, Nicola ; Griffiths, Oliver ; Croxford, Pip ; Sequenza, Peter ; Lazarus, Rajeka ; Walters, Rhian ; Marlow, Robin ; Heath, Robyn ; Antico, Rupert ; Nammuni Arachchge, Sandi ; Suppiah, Seevakumar ; Mona, Taslima ; Riaz, Tawassal ; Mackay, Vicki ; Maseko, Zandile ; Taylor, Zoe ; Friedrich, Zsolt ; Szasz-Benczur, Zsuzsa ; Avon CAP Research Group</creatorcontrib><description>Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.
A prospective single-centre test-negative design case–control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO2 (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and community infection prevalence.
935 controls and 546 cases were hospitalised during the Delta period, with 721 controls and 372 cases hospitalised during the Omicron study period. Two-dose BNT162b2 was associated with VE 82.5% [95% confidence interval 76.2%–87.2%] against hospitalisation following Delta infection, 63.3% [26.9–81.8%], 58.5% [24.8–77.3%], and 51.5% [16.7–72.1%] against LOS >3 days, WHO COVID Score >5, and requirement for FiO2 >28% respectively. Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9–49.3%], with sensitivity analyses ranging from 28.8–72.6%. Protection against LOS >3 days, WHO COVID Score >5 and requirement for FiO2 >28% was 56.1% [20.6–76.5%], 58.8% [31.2–75.8%], and 41.5% [−0.4–66.3%], respectively. In the UK, BNT162b2 was prioritised for high-risk individuals and those aged >75 years. In the latter group we found a higher estimate of VE against hospitalisation of 47.2% [16.8–66.6%].
BNT162b2 vaccination results in risk reductions for hospitalisation and multiple patient outcomes following Delta and Omicron COVID-19 infection, particularly in older adults. BNT162b2 remains effective against severe SARS-CoV-2 disease.
AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.</description><identifier>ISSN: 2666-7762</identifier><identifier>EISSN: 2666-7762</identifier><identifier>DOI: 10.1016/j.lanepe.2022.100552</identifier><identifier>PMID: 36506791</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>COVID-19 ; Respiratory infection ; SARS-CoV-2 ; Vaccination</subject><ispartof>The Lancet regional health. Europe, 2023-02, Vol.25, p.100552-100552, Article 100552</ispartof><rights>2022 The Author(s)</rights><rights>2022 The Author(s).</rights><rights>2022 The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-21651b4425dbd1f186137a6d7626268938e64bccd6c1b2ffbae153a65451d4f03</citedby><cites>FETCH-LOGICAL-c463t-21651b4425dbd1f186137a6d7626268938e64bccd6c1b2ffbae153a65451d4f03</cites><orcidid>0000-0003-1756-5668</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728025/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728025/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36506791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chatzilena, Anastasia</creatorcontrib><creatorcontrib>Hyams, Catherine</creatorcontrib><creatorcontrib>Challen, Rob</creatorcontrib><creatorcontrib>Marlow, Robin</creatorcontrib><creatorcontrib>King, Jade</creatorcontrib><creatorcontrib>Adegbite, David</creatorcontrib><creatorcontrib>Kinney, Jane</creatorcontrib><creatorcontrib>Clout, Madeleine</creatorcontrib><creatorcontrib>Maskell, Nick</creatorcontrib><creatorcontrib>Oliver, Jennifer</creatorcontrib><creatorcontrib>Danon, Leon</creatorcontrib><creatorcontrib>Finn, Adam</creatorcontrib><creatorcontrib>Morley, Anna</creatorcontrib><creatorcontrib>Langdon, Amelia</creatorcontrib><creatorcontrib>Turner, Anabella</creatorcontrib><creatorcontrib>Mattocks, Anya</creatorcontrib><creatorcontrib>Osborne, Bethany</creatorcontrib><creatorcontrib>Grimes, Charli</creatorcontrib><creatorcontrib>Mitchell, Claire</creatorcontrib><creatorcontrib>Bridgeman, Emma</creatorcontrib><creatorcontrib>Scott, Emma</creatorcontrib><creatorcontrib>Perkins, Fiona</creatorcontrib><creatorcontrib>Bayley, Francesca</creatorcontrib><creatorcontrib>Ruffino, Gabriella</creatorcontrib><creatorcontrib>Valentine, Gabriella</creatorcontrib><creatorcontrib>Tilzey, Grace</creatorcontrib><creatorcontrib>Kellett Wright, Johanna</creatorcontrib><creatorcontrib>Brzezinska, Julia</creatorcontrib><creatorcontrib>Cloake, Julie</creatorcontrib><creatorcontrib>Milutinovic, Katarina</creatorcontrib><creatorcontrib>Helliker, Kate</creatorcontrib><creatorcontrib>Maughan, Katie</creatorcontrib><creatorcontrib>Fox, Kazminder</creatorcontrib><creatorcontrib>Minou, Konstantina</creatorcontrib><creatorcontrib>Ward, Lana</creatorcontrib><creatorcontrib>Fleming, Leah</creatorcontrib><creatorcontrib>Morrison, Leigh</creatorcontrib><creatorcontrib>Smart, Lily</creatorcontrib><creatorcontrib>Wright, Louise</creatorcontrib><creatorcontrib>Grimwood, Lucy</creatorcontrib><creatorcontrib>Bellavia, Maddalena</creatorcontrib><creatorcontrib>Vasquez, Marianne</creatorcontrib><creatorcontrib>Garcia Gonzalez, Maria</creatorcontrib><creatorcontrib>Jeenes-Flanagan, Milo</creatorcontrib><creatorcontrib>Chang, Natalie</creatorcontrib><creatorcontrib>Grace, Niall</creatorcontrib><creatorcontrib>Manning, Nicola</creatorcontrib><creatorcontrib>Griffiths, Oliver</creatorcontrib><creatorcontrib>Croxford, Pip</creatorcontrib><creatorcontrib>Sequenza, Peter</creatorcontrib><creatorcontrib>Lazarus, Rajeka</creatorcontrib><creatorcontrib>Walters, Rhian</creatorcontrib><creatorcontrib>Marlow, Robin</creatorcontrib><creatorcontrib>Heath, Robyn</creatorcontrib><creatorcontrib>Antico, Rupert</creatorcontrib><creatorcontrib>Nammuni Arachchge, Sandi</creatorcontrib><creatorcontrib>Suppiah, Seevakumar</creatorcontrib><creatorcontrib>Mona, Taslima</creatorcontrib><creatorcontrib>Riaz, Tawassal</creatorcontrib><creatorcontrib>Mackay, Vicki</creatorcontrib><creatorcontrib>Maseko, Zandile</creatorcontrib><creatorcontrib>Taylor, Zoe</creatorcontrib><creatorcontrib>Friedrich, Zsolt</creatorcontrib><creatorcontrib>Szasz-Benczur, Zsuzsa</creatorcontrib><creatorcontrib>Avon CAP Research Group</creatorcontrib><title>Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study</title><title>The Lancet regional health. Europe</title><addtitle>Lancet Reg Health Eur</addtitle><description>Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.
A prospective single-centre test-negative design case–control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO2 (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and community infection prevalence.
935 controls and 546 cases were hospitalised during the Delta period, with 721 controls and 372 cases hospitalised during the Omicron study period. Two-dose BNT162b2 was associated with VE 82.5% [95% confidence interval 76.2%–87.2%] against hospitalisation following Delta infection, 63.3% [26.9–81.8%], 58.5% [24.8–77.3%], and 51.5% [16.7–72.1%] against LOS >3 days, WHO COVID Score >5, and requirement for FiO2 >28% respectively. Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9–49.3%], with sensitivity analyses ranging from 28.8–72.6%. Protection against LOS >3 days, WHO COVID Score >5 and requirement for FiO2 >28% was 56.1% [20.6–76.5%], 58.8% [31.2–75.8%], and 41.5% [−0.4–66.3%], respectively. In the UK, BNT162b2 was prioritised for high-risk individuals and those aged >75 years. In the latter group we found a higher estimate of VE against hospitalisation of 47.2% [16.8–66.6%].
BNT162b2 vaccination results in risk reductions for hospitalisation and multiple patient outcomes following Delta and Omicron COVID-19 infection, particularly in older adults. BNT162b2 remains effective against severe SARS-CoV-2 disease.
AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.</description><subject>COVID-19</subject><subject>Respiratory infection</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><issn>2666-7762</issn><issn>2666-7762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9UsFO3DAUDFWrgih_UFU-wiFpnpM4mx4qwUJbECpSoVwtx35hvcrai-0s2lv_oX_YL6k3Sym9VDk4z555njeeJHkLeQY5sPfzrBcGl5jRnNK4lVcVfZHsUcZYWteMvnz2v5sceD_P85xWUFAoXye7BatyVjewt7Nz1nUog16hQe-J7cjJ1xtgtKVkenV7fppCQ1ZCSm1E0NYQbcjSYUSPVYTPrF_qIHrtR4AnwijiI8IhUdqj8LghCTX0wZMHHWbk-vjbdTq1tyklp9gHQQ5PMsgY1Bk9GulXCy1dbD_uQ1bR5iiKcFqYQFoMD4iGXAwGSZweRsbF0K83Ff1ARBQYNW2HIgF9IAbvxFjJqObXj5_SmuBsT3wY1PpN8qoTvceDx3U_-f7p7Gb6Jb28-nw-Pb5MZcmKkFJgFbRlSSvVKuhgwqCoBVPR4PhNmmKCrGylVExCS7uuFQhVIVhVVqDKLi_2k4_bvsuhXaCS0UIner50eiHcmluh-b8nRs_4nV3xpqaT-HaxweFjA2fvhzgXX2gvsd8kwQ6e07oqGGugaCK03EKjjd477J6ugZxvAsTnfBsgvjGNbwMUae-eS3wi_YnL3xkwGrXS6LiXGo1EpV00nCur_3_Db5ZP13Q</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Chatzilena, Anastasia</creator><creator>Hyams, Catherine</creator><creator>Challen, Rob</creator><creator>Marlow, Robin</creator><creator>King, Jade</creator><creator>Adegbite, David</creator><creator>Kinney, Jane</creator><creator>Clout, Madeleine</creator><creator>Maskell, Nick</creator><creator>Oliver, Jennifer</creator><creator>Danon, Leon</creator><creator>Finn, Adam</creator><creator>Morley, Anna</creator><creator>Langdon, Amelia</creator><creator>Turner, Anabella</creator><creator>Mattocks, Anya</creator><creator>Osborne, Bethany</creator><creator>Grimes, Charli</creator><creator>Mitchell, Claire</creator><creator>Bridgeman, Emma</creator><creator>Scott, Emma</creator><creator>Perkins, Fiona</creator><creator>Bayley, Francesca</creator><creator>Ruffino, Gabriella</creator><creator>Valentine, Gabriella</creator><creator>Tilzey, Grace</creator><creator>Kellett Wright, Johanna</creator><creator>Brzezinska, Julia</creator><creator>Cloake, Julie</creator><creator>Milutinovic, Katarina</creator><creator>Helliker, Kate</creator><creator>Maughan, Katie</creator><creator>Fox, Kazminder</creator><creator>Minou, Konstantina</creator><creator>Ward, Lana</creator><creator>Fleming, Leah</creator><creator>Morrison, Leigh</creator><creator>Smart, Lily</creator><creator>Wright, Louise</creator><creator>Grimwood, Lucy</creator><creator>Bellavia, Maddalena</creator><creator>Vasquez, Marianne</creator><creator>Garcia Gonzalez, Maria</creator><creator>Jeenes-Flanagan, Milo</creator><creator>Chang, Natalie</creator><creator>Grace, Niall</creator><creator>Manning, Nicola</creator><creator>Griffiths, Oliver</creator><creator>Croxford, Pip</creator><creator>Sequenza, Peter</creator><creator>Lazarus, Rajeka</creator><creator>Walters, Rhian</creator><creator>Marlow, Robin</creator><creator>Heath, Robyn</creator><creator>Antico, Rupert</creator><creator>Nammuni Arachchge, Sandi</creator><creator>Suppiah, Seevakumar</creator><creator>Mona, Taslima</creator><creator>Riaz, Tawassal</creator><creator>Mackay, Vicki</creator><creator>Maseko, Zandile</creator><creator>Taylor, Zoe</creator><creator>Friedrich, Zsolt</creator><creator>Szasz-Benczur, Zsuzsa</creator><general>Elsevier Ltd</general><general>The Author(s). Published by Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1756-5668</orcidid></search><sort><creationdate>20230201</creationdate><title>Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study</title><author>Chatzilena, Anastasia ; Hyams, Catherine ; Challen, Rob ; Marlow, Robin ; King, Jade ; Adegbite, David ; Kinney, Jane ; Clout, Madeleine ; Maskell, Nick ; Oliver, Jennifer ; Danon, Leon ; Finn, Adam ; Morley, Anna ; Langdon, Amelia ; Turner, Anabella ; Mattocks, Anya ; Osborne, Bethany ; Grimes, Charli ; Mitchell, Claire ; Bridgeman, Emma ; Scott, Emma ; Perkins, Fiona ; Bayley, Francesca ; Ruffino, Gabriella ; Valentine, Gabriella ; Tilzey, Grace ; Kellett Wright, Johanna ; Brzezinska, Julia ; Cloake, Julie ; Milutinovic, Katarina ; Helliker, Kate ; Maughan, Katie ; Fox, Kazminder ; Minou, Konstantina ; Ward, Lana ; Fleming, Leah ; Morrison, Leigh ; Smart, Lily ; Wright, Louise ; Grimwood, Lucy ; Bellavia, Maddalena ; Vasquez, Marianne ; Garcia Gonzalez, Maria ; Jeenes-Flanagan, Milo ; Chang, Natalie ; Grace, Niall ; Manning, Nicola ; Griffiths, Oliver ; Croxford, Pip ; Sequenza, Peter ; Lazarus, Rajeka ; Walters, Rhian ; Marlow, Robin ; Heath, Robyn ; Antico, Rupert ; Nammuni Arachchge, Sandi ; Suppiah, Seevakumar ; Mona, Taslima ; Riaz, Tawassal ; Mackay, Vicki ; Maseko, Zandile ; Taylor, Zoe ; Friedrich, Zsolt ; Szasz-Benczur, Zsuzsa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-21651b4425dbd1f186137a6d7626268938e64bccd6c1b2ffbae153a65451d4f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19</topic><topic>Respiratory infection</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chatzilena, Anastasia</creatorcontrib><creatorcontrib>Hyams, Catherine</creatorcontrib><creatorcontrib>Challen, Rob</creatorcontrib><creatorcontrib>Marlow, Robin</creatorcontrib><creatorcontrib>King, Jade</creatorcontrib><creatorcontrib>Adegbite, David</creatorcontrib><creatorcontrib>Kinney, Jane</creatorcontrib><creatorcontrib>Clout, Madeleine</creatorcontrib><creatorcontrib>Maskell, Nick</creatorcontrib><creatorcontrib>Oliver, Jennifer</creatorcontrib><creatorcontrib>Danon, Leon</creatorcontrib><creatorcontrib>Finn, Adam</creatorcontrib><creatorcontrib>Morley, Anna</creatorcontrib><creatorcontrib>Langdon, Amelia</creatorcontrib><creatorcontrib>Turner, Anabella</creatorcontrib><creatorcontrib>Mattocks, Anya</creatorcontrib><creatorcontrib>Osborne, Bethany</creatorcontrib><creatorcontrib>Grimes, Charli</creatorcontrib><creatorcontrib>Mitchell, Claire</creatorcontrib><creatorcontrib>Bridgeman, Emma</creatorcontrib><creatorcontrib>Scott, Emma</creatorcontrib><creatorcontrib>Perkins, Fiona</creatorcontrib><creatorcontrib>Bayley, Francesca</creatorcontrib><creatorcontrib>Ruffino, Gabriella</creatorcontrib><creatorcontrib>Valentine, Gabriella</creatorcontrib><creatorcontrib>Tilzey, Grace</creatorcontrib><creatorcontrib>Kellett Wright, Johanna</creatorcontrib><creatorcontrib>Brzezinska, Julia</creatorcontrib><creatorcontrib>Cloake, Julie</creatorcontrib><creatorcontrib>Milutinovic, Katarina</creatorcontrib><creatorcontrib>Helliker, Kate</creatorcontrib><creatorcontrib>Maughan, Katie</creatorcontrib><creatorcontrib>Fox, Kazminder</creatorcontrib><creatorcontrib>Minou, Konstantina</creatorcontrib><creatorcontrib>Ward, Lana</creatorcontrib><creatorcontrib>Fleming, Leah</creatorcontrib><creatorcontrib>Morrison, Leigh</creatorcontrib><creatorcontrib>Smart, Lily</creatorcontrib><creatorcontrib>Wright, Louise</creatorcontrib><creatorcontrib>Grimwood, Lucy</creatorcontrib><creatorcontrib>Bellavia, Maddalena</creatorcontrib><creatorcontrib>Vasquez, Marianne</creatorcontrib><creatorcontrib>Garcia Gonzalez, Maria</creatorcontrib><creatorcontrib>Jeenes-Flanagan, Milo</creatorcontrib><creatorcontrib>Chang, Natalie</creatorcontrib><creatorcontrib>Grace, Niall</creatorcontrib><creatorcontrib>Manning, Nicola</creatorcontrib><creatorcontrib>Griffiths, Oliver</creatorcontrib><creatorcontrib>Croxford, Pip</creatorcontrib><creatorcontrib>Sequenza, Peter</creatorcontrib><creatorcontrib>Lazarus, Rajeka</creatorcontrib><creatorcontrib>Walters, Rhian</creatorcontrib><creatorcontrib>Marlow, Robin</creatorcontrib><creatorcontrib>Heath, Robyn</creatorcontrib><creatorcontrib>Antico, Rupert</creatorcontrib><creatorcontrib>Nammuni Arachchge, Sandi</creatorcontrib><creatorcontrib>Suppiah, Seevakumar</creatorcontrib><creatorcontrib>Mona, Taslima</creatorcontrib><creatorcontrib>Riaz, Tawassal</creatorcontrib><creatorcontrib>Mackay, Vicki</creatorcontrib><creatorcontrib>Maseko, Zandile</creatorcontrib><creatorcontrib>Taylor, Zoe</creatorcontrib><creatorcontrib>Friedrich, Zsolt</creatorcontrib><creatorcontrib>Szasz-Benczur, Zsuzsa</creatorcontrib><creatorcontrib>Avon CAP Research Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet regional health. Europe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chatzilena, Anastasia</au><au>Hyams, Catherine</au><au>Challen, Rob</au><au>Marlow, Robin</au><au>King, Jade</au><au>Adegbite, David</au><au>Kinney, Jane</au><au>Clout, Madeleine</au><au>Maskell, Nick</au><au>Oliver, Jennifer</au><au>Danon, Leon</au><au>Finn, Adam</au><au>Morley, Anna</au><au>Langdon, Amelia</au><au>Turner, Anabella</au><au>Mattocks, Anya</au><au>Osborne, Bethany</au><au>Grimes, Charli</au><au>Mitchell, Claire</au><au>Bridgeman, Emma</au><au>Scott, Emma</au><au>Perkins, Fiona</au><au>Bayley, Francesca</au><au>Ruffino, Gabriella</au><au>Valentine, Gabriella</au><au>Tilzey, Grace</au><au>Kellett Wright, Johanna</au><au>Brzezinska, Julia</au><au>Cloake, Julie</au><au>Milutinovic, Katarina</au><au>Helliker, Kate</au><au>Maughan, Katie</au><au>Fox, Kazminder</au><au>Minou, Konstantina</au><au>Ward, Lana</au><au>Fleming, Leah</au><au>Morrison, Leigh</au><au>Smart, Lily</au><au>Wright, Louise</au><au>Grimwood, Lucy</au><au>Bellavia, Maddalena</au><au>Vasquez, Marianne</au><au>Garcia Gonzalez, Maria</au><au>Jeenes-Flanagan, Milo</au><au>Chang, Natalie</au><au>Grace, Niall</au><au>Manning, Nicola</au><au>Griffiths, Oliver</au><au>Croxford, Pip</au><au>Sequenza, Peter</au><au>Lazarus, Rajeka</au><au>Walters, Rhian</au><au>Marlow, Robin</au><au>Heath, Robyn</au><au>Antico, Rupert</au><au>Nammuni Arachchge, Sandi</au><au>Suppiah, Seevakumar</au><au>Mona, Taslima</au><au>Riaz, Tawassal</au><au>Mackay, Vicki</au><au>Maseko, Zandile</au><au>Taylor, Zoe</au><au>Friedrich, Zsolt</au><au>Szasz-Benczur, Zsuzsa</au><aucorp>Avon CAP Research Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study</atitle><jtitle>The Lancet regional health. Europe</jtitle><addtitle>Lancet Reg Health Eur</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>25</volume><spage>100552</spage><epage>100552</epage><pages>100552-100552</pages><artnum>100552</artnum><issn>2666-7762</issn><eissn>2666-7762</eissn><abstract>Whilst other studies have reported the effectiveness of mRNA vaccination against hospitalisation, including emergency department or intensive care admission, few have assessed effectiveness against other more clinically robust indices of COVID-19 severity.
A prospective single-centre test-negative design case–control study of adults hospitalised with COVID-19 disease or other acute respiratory disease between 1 June 2021 and 20 July 2022. We assessed VE (vaccine effectiveness) against hospitalisation, length of stay [LOS] >3 days, WHO COVID Score >5 and supplementary oxygen FiO2 (fraction inspired oxygen) >28%, conducting regression analyses controlling for age, gender, index of multiple deprivation, Charlson comorbidity index, time, and community infection prevalence.
935 controls and 546 cases were hospitalised during the Delta period, with 721 controls and 372 cases hospitalised during the Omicron study period. Two-dose BNT162b2 was associated with VE 82.5% [95% confidence interval 76.2%–87.2%] against hospitalisation following Delta infection, 63.3% [26.9–81.8%], 58.5% [24.8–77.3%], and 51.5% [16.7–72.1%] against LOS >3 days, WHO COVID Score >5, and requirement for FiO2 >28% respectively. Three-dose BNT162b2 protection against hospitalisation with Omicron infection was 30.9% [5.9–49.3%], with sensitivity analyses ranging from 28.8–72.6%. Protection against LOS >3 days, WHO COVID Score >5 and requirement for FiO2 >28% was 56.1% [20.6–76.5%], 58.8% [31.2–75.8%], and 41.5% [−0.4–66.3%], respectively. In the UK, BNT162b2 was prioritised for high-risk individuals and those aged >75 years. In the latter group we found a higher estimate of VE against hospitalisation of 47.2% [16.8–66.6%].
BNT162b2 vaccination results in risk reductions for hospitalisation and multiple patient outcomes following Delta and Omicron COVID-19 infection, particularly in older adults. BNT162b2 remains effective against severe SARS-CoV-2 disease.
AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36506791</pmid><doi>10.1016/j.lanepe.2022.100552</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1756-5668</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2666-7762 |
| ispartof | The Lancet regional health. Europe, 2023-02, Vol.25, p.100552-100552, Article 100552 |
| issn | 2666-7762 2666-7762 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9728025 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | COVID-19 Respiratory infection SARS-CoV-2 Vaccination |
| title | Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A17%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20BNT162b2%20COVID-19%20vaccination%20in%20prevention%20of%20hospitalisations%20and%20severe%20disease%20in%20adults%20with%20SARS-CoV-2%20Delta%20(B.1.617.2)%20and%20Omicron%20(B.1.1.529)%20variant%20between%20June%202021%20and%20July%202022:%20a%20prospective%20test%20negative%20case%E2%80%93control%20study&rft.jtitle=The%20Lancet%20regional%20health.%20Europe&rft.au=Chatzilena,%20Anastasia&rft.aucorp=Avon%20CAP%20Research%20Group&rft.date=2023-02-01&rft.volume=25&rft.spage=100552&rft.epage=100552&rft.pages=100552-100552&rft.artnum=100552&rft.issn=2666-7762&rft.eissn=2666-7762&rft_id=info:doi/10.1016/j.lanepe.2022.100552&rft_dat=%3Cproquest_pubme%3E2753669139%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2753669139&rft_id=info:pmid/36506791&rft_els_id=S2666776222002484&rfr_iscdi=true |